These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 25314989)

  • 1. [Don't forget the Marevan!].
    Bjerke E
    Tidsskr Nor Laegeforen; 2014 Oct; 134(19):1860. PubMed ID: 25314989
    [No Abstract]   [Full Text] [Related]  

  • 2. [Re: Don't forget the Marevan!].
    Langaas HC; Schjøtt J
    Tidsskr Nor Laegeforen; 2014 Nov; 134(22):2125. PubMed ID: 25423967
    [No Abstract]   [Full Text] [Related]  

  • 3. The relationship between maintenance dosages of three vitamin K antagonists: acenocoumarol, warfarin and phenprocoumon.
    van Leeuwen Y; Rosendaal FR; van der Meer FJ
    Thromb Res; 2008; 123(2):225-30. PubMed ID: 18407321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Warfarin or acenocoumarol: which is better in the management of oral anticoagulants?
    Barcellona D; Vannini ML; Fenu L; Balestrieri C; Marongiu F
    Thromb Haemost; 1998 Dec; 80(6):899-902. PubMed ID: 9869157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Warfarin or acenocoumarol is better in the anticoagulant treatment of chronic atrial fibrillation?].
    Lengyel M;
    Orv Hetil; 2004 Dec; 145(52):2619-21. PubMed ID: 15724697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transition from acenocoumarol to warfarin in a 12-year-old child.
    Hakacova N; Björkhem G; Hanséus K
    Congenit Heart Dis; 2011; 6(6):661-4. PubMed ID: 21501391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The efficacy and safety of acenocoumarol and warfarin therapy in patients with lower limb deep vein thrombosis].
    Bernát SI; Rókusz L
    Orv Hetil; 2012 May; 153(20):786-90. PubMed ID: 22580505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of the -1639G > A polymorphism of the VKORC1 gene on the dose of oral anticoagulants acenocoumarol, and warfarin in Chilean patients: alternative models of inheritance].
    López-Hernández D
    Rev Med Chil; 2016 Apr; 144(4):539-41. PubMed ID: 27401392
    [No Abstract]   [Full Text] [Related]  

  • 9. [Oral anti-coagulation as a primary care service. A necessity that cannot be postponed].
    Melguizo Jiménez M; Ortega del Moral A; Castro Gómez JA; Aguilar Navas L
    Aten Primaria; 2007 Aug; 39(8):453. PubMed ID: 17692240
    [No Abstract]   [Full Text] [Related]  

  • 10. Point-of-care testing and INR within-subject variation in patients receiving a constant dose of vitamin K antagonist.
    van den Besselaar AM; Biedermann JS; Kruip MJ
    Thromb Haemost; 2015 Nov; 114(6):1260-7. PubMed ID: 26202616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Long-term anticoagulant therapy in old age].
    Bán A
    Orv Hetil; 1984 Jan; 125(4):205-10. PubMed ID: 6694840
    [No Abstract]   [Full Text] [Related]  

  • 12. VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients.
    Markatos CN; Grouzi E; Politou M; Gialeraki A; Merkouri E; Panagou I; Spiliotopoulou I; Travlou A
    Pharmacogenomics; 2008 Nov; 9(11):1631-8. PubMed ID: 19018719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary prophylaxis with low molecular weight heparin: the dose?
    Horne MK
    Thromb Haemost; 2001 Oct; 86(4):1129. PubMed ID: 11686343
    [No Abstract]   [Full Text] [Related]  

  • 14. Warfarin, genes, and the (health care) environment.
    Kazi DS; Hlatky MA
    JAMA Intern Med; 2014 Aug; 174(8):1338-9. PubMed ID: 24934523
    [No Abstract]   [Full Text] [Related]  

  • 15. CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences.
    Takahashi H; Wilkinson GR; Padrini R; Echizen H
    Clin Pharmacol Ther; 2004 May; 75(5):376-80. PubMed ID: 15116049
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical and genetic factors influencing acenocoumarol dosing: a cross-sectional study.
    Vázquez C; Orlova M; Scibona P; Ferreyro BL; Otero V; Jáuregui EG; Arbelbide J; Belloso WH
    Blood Coagul Fibrinolysis; 2018 Sep; 29(6):496-500. PubMed ID: 29916837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Oral anticoagulants: warfarin or acenocumarol?].
    Roncalés FJ
    Med Clin (Barc); 2008 Jun; 131(3):98-100. PubMed ID: 18590624
    [No Abstract]   [Full Text] [Related]  

  • 18. The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients.
    Montes R; Ruiz de Gaona E; Martínez-González MA; Alberca I; Hermida J
    Br J Haematol; 2006 Apr; 133(2):183-7. PubMed ID: 16611310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of pharmacogenetic testing.
    Pocinki AG
    JAMA Intern Med; 2015 Feb; 175(2):314. PubMed ID: 25642672
    [No Abstract]   [Full Text] [Related]  

  • 20. The value of pharmacogenetic testing—reply.
    Kazi DS; Hlatky MA
    JAMA Intern Med; 2015 Feb; 175(2):314-5. PubMed ID: 25642673
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.